United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
United Therapeutics Corp. (UTHR) PT Lowered to $223 at Jefferies
February 25, 2022 8:44 AM ESTJefferies analyst Eun Yang lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $223.00 (from $235.00) while maintaining a Buy rating.
The analyst commented, "Though disappointing, there are rational explanations for 4Q21 key products sales miss & another FDA approval delay for... More
United Therapeutics (UTHR) Misses Q4 EPS by 21c
February 24, 2022 6:10 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.51, $0.21 worse than the analyst estimate of $3.72. Revenue for the quarter came in at $415.2 million versus the consensus estimate of $427.62 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More